The preventive effect on in-stent restenosis of overlapped drug-eluting stents for treating diffuse coronary artery disease

Korean Circulation Journal

Volumn 36, Issue 1, 2006, Pages 17-23

  Kim, Weon ^a   Jeong, Myung Ho ^a   Cho, Jae Yeoung ^a   Cho, Jung Sun ^a   Hwang, Seung Hwan ^a   Lee, Sang Rok ^a   Lim, Sang Yup ^a   Hong, Young Joon ^a   Hong, Seo Na ^a   Kim, Kye Hun ^a   Son, Il Suk ^a   Park, Hyung Wook ^a   Kim, Ju Han ^a   Ahn, Young Keun ^a   Cho, Jeong Gwan ^a   Park, Jong Chun ^a   Kang, Jung Chaee ^a  

^a Chonnam National University Medical School   (South Korea)

Author keywords

Coronary disease; Coronary restenosis; Drugs; Stents

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; DALTEPARIN; HEPARIN; PACLITAXEL; RAPAMYCIN;

ADULT; AGED; ANGIOCARDIOGRAPHY; ARTERY DIAMETER; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; DRUG ELUTING STENT; FEMALE; FOLLOW UP; HEART DEATH; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HUMAN; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; RESTENOSIS; SAFETY; THROMBOSIS;

EID: 33644583038     PISSN: 17385520     EISSN: 17385555     Source Type: Journal    
DOI: 10.4070/kcj.2006.36.1.17     Document Type: Article

References (30)

1. Kastrati A, Elezi S, Dirschinger J, Hadamitzky M, Neumann F, Schomig A. Influence of lesion length on restenosis after coronary stent placement. Am J Cardiol 1999;83:1617-22.
2. Kornowski R, Mehran R, Hong MK, et al. Procedural results and late clinical outcomes after placement of three or more stents in single coronary lesions. Circulation 1998;97:1355-61.
3. Serruys PW, Foley DP, Suttorp MJ, et al. A randomized comparison of the value of additional stenting after optimal balloon angioplasty for long coronary lesions: final results of the additional value of NIR stents for treatment of long coronary lesions (ADVANCE) study. J Am Coll Cardiol 2002;39:393-9.
4. Oemrawsingh PV, Mintz GS, Schalij MJ, Winderman AH, Jukema JW, van der Wall EE. Intravascular ultrasound guidance improves angiographic and clinical outcome of stent implantation for long coronary artery stenoses: final results of a randomized comparison with angiographic guidance (TULIP Study). Circulation 2003;107:62-7.
5. Kornowski R, Bhargava B, Fuchs S, et al. Procedural results and late clinical outcomes after percutaneous interventions using long (≥25 mm) versus short (<20 mm) stents. J Am Coll Cardiol 2000;35:612-8.
6. Doss M, Martens S, Wood P, Tsoukalas I, Moritz A. Five-year follow-up after long plaque-bridging coronary arteriotomy for diffuse coronary artery disease. Thorac Cardiovasc Surg 2003;51:318-21.
7. Santini F, Casali G, Lusini M, et al. Mid-term results after extensive vein patch reconstruction and internal mammary grafting of the diffusely diseased left anterior descending coronary artery. Eur J Cardiothorac Surg 2002;21:1020-5.
8. Kobayashi Y, de Gregorio J, Kobayashi N, et al. Stented segment length as an independent predictor of restenosis. J Am Coll Cardiol 1999;34:651-9.
9. Moses JW, Leon MB, Popma JJ, et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 2003;349:1315-23.
10. Lemos PA, Hoye A, Goedhart D, et al. Clinical, angiographic, and procedural predictors of angiographic restenosis after sirolimus-eluting stent implantation in complex patients. Circulation 2004;109:1366-70.
11. Degertekin M, Arampatzis CA, Lemos PA, et al. Very long sirolimus-eluting stent implantation for de novo coronary lesions. Am J Cardiol 2004;93:826-9.
12. Sawhney N, Moses JW, Leon MB, et al. Treatment of left anterior descending coronary artery disease with sirolimus eluting stents. Circulation 2004;110:374-9.
13. Tsagalou E, Chieffo A, Iakovou I, et al. Multiple overlapping drug-eluting stents to treat diffuse disease of the left anterior descending coronary artery. J Am Coll Cardiol 2005;45:1570-3.
14. Finn AV, Kolodgie FD, Harnek J, et al. Differential response of delayed healing and persistent inflammation at sites of overlapping sirolimus- or paclitaxel-eluting stents. Circulation 2005;112:270-8.
15. Schalij MJ, Udayachalerm W, Oemrawsingh P, Jukema JW, Reiber JH, Bruschke AV. Stenting of long coronary artery lesions: initial angiographic results and 6-month clinical outcome of the micro stent II-XL. Catheter Cardiovasc Interv 1999;48:105-12.
16. Colombo A, de Gregorio J, Moussa I, et al. Intravascular ultrasound-guided percutaneous transluminal coronary angioplasty with provisional spot stenting for treatment of long coronary lesions, J Am Coll Cardiol 2001;38:1427-33.
17. Lemos PA, Saia F, Ligthart JM, et al. Coronary restenosis after sirolimus-eluting stent implantation: morphological description and mechanistic analysis from a consecutive series of cases. Circulation 2003;108:257-60.
18. Balakrishnan B, Tzafriri AR, Seifert P, Groothuis A, Rogers C, Edelman ER. Strut position, blood flow, and drug deposition: implications for single and overlapping drug-eluting stents. Circulation 2005;111:2958-65.
19. Ong AT, McFadden EP, Regar E, de Jaegere PP, van Domburg RT, Serruys PW. Late angiographic stent thrombosis (LAST) events with drug-eluting stents. J Am Coll Cardiol 2005;45:2088-92.
20. McFadden EP, Stabile E, Regar E, et al. Late thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapy. Lancet 2004;364:1519-21.
21. Kim W, Jeong MH, Cha KS, et al. The effect of anti-oxidants (carvedilol and probucol) loaded stents in a porcine coronary restenosis model. Circ J 2005;69:101-6.
22. Kim W, Jeong MH, Hong YJ, et al. The long-term clinical results of a platelet glycoprotein IIb/IIIa receptor blocker (Abciximab: ReoPro®) coated stent in patients with acute myocardial infarction. Korean Circ J 2004;34:1063-9.
23. Kim W, Jeong MH, Hong YJ, et al. The long-term clinical results of a platelet glycoprotein IIb/IIIa receptor blocker (Abciximab: ReoPro®) coated stent in patient with coronary artery disease. Korean J Intern Med 2004;19:220-9.
24. Hong YJ, Jeong MH, Kim W, et al. Effect of abciximab-coated stent on in-stent intimal hyperplasia in human coronary arteries. Am J Cardiol 2004;94:1050-4.
25. Park OY, Jeong MH, Kim JH, et al. The inhibitory effects of platelet glycoprotein IIb/IIIa receptor blocker-coated stent on neointima formation and inflammatory response in porcine coronary stent restenosis. Korean Circ J 2003;33:439-45.
26. Lim SY, Jeong MH. Is heparin-coated stent effective in patients with acute myocardial infarction? Korean Circ J 2004;34:537-9.
27. Kaiser C, Brunner-La Rocca HP, Buser PT, et al. Incremental cost-effectiveness of drug-eluting stents compared with a third-generation bare-metal stent in a real-world setting. Lancet 2005;366:921-9.
28. Kim KH, Jeong MH, Hong SN, et al. The clinical effects of drug-eluting stents for the treatment of coronary in-stent restenosis. Korean Circ J 2005;35:443-7.
29. Yang BR, Jeong MH, Park OY, et al. A case of recurrent in-stent restenosis with abundant proteoglycan component. Korean Circ J 2003;33:827-31.
30. Neumann FJ, Desmet W, Grube E, et al. Effectiveness and safety of sirolimus-eluting stents in the treatment of restenosis after coronary stent placement. Circulation 2005;111:2107-11.